Cancer Patients Face Dire Consequences as Pancreatic Enzyme Therapy Shortage Deepens

The ongoing shortage of pancreatic enzyme replacement therapy (PERT) is raising alarms among cancer charities and healthcare professionals, who warn that the crisis could lead to tragic outcomes for thousands of patients across the UK. The Hampshire-based charity, which supports individuals diagnosed with various cancers—including pancreatic, liver, colorectal, abdominal, and neuroendocrine cancers—has voiced its concerns over the implications of this shortage. Estimates suggest that around 20,000 people are currently affected by the unavailability of PERT, commonly known by its brand name, Creon. This medication is crucial for patients whose digestive systems cannot produce enough enzymes to properly digest food, a frequent issue for those battling advanced stages of cancer. The absence of this vital drug could have severe consequences, potentially leading to complications such as sepsis and diabetes, as noted by Mr. Pearce, a former pancreatic cancer surgeon. Mr. Pearce emphasized the urgency of addressing this issue, warning that without immediate interim solutions, the potential for "excess and avoidable deaths" looms large. He expressed deep concern over the continued vulnerability of patients, despite a safety alert issued by the National Patient Safety Agency (NPSA) that suggests relaxing procurement rules to facilitate the importation of PERT from unlicensed sources. However, Mr. Pearce criticized the lack of evidence indicating that patients have been able to access these alternative supplies. Reports have emerged of patients "scouring the country" in search of pharmacies that might have the medication in stock, highlighting a distressing reality for those in dire need. A spokesperson from the PLANETS charity outlined additional factors contributing to the shortage. They pointed to the absence of a UK manufacturer and a global surge in demand for PERT as significant challenges. Furthermore, the current NHS prescribing regulations complicate the situation; these rules prevent pharmacists from substituting a different, yet equivalent, product when a specific brand is requested in a prescription. The restrictions on importing supplies from unlicensed sources, particularly those available from US manufacturers, further exacerbate the crisis. As the Department for Health and Social Care has been approached for comment, the hope remains that swift action will be taken to address these pressing supply issues. The charity and healthcare professionals alike are advocating for immediate changes to ensure that patients do not suffer due to the lack of accessible treatment options. The implications of this shortage are profound, underscoring the need for robust solutions to prevent unnecessary loss of life among some of the most vulnerable individuals in our society.